Paul A. Grayson is Director at Skye Bioscience, Inc. (SKYE). They have made 1 open-market trade across 1 company since 2024, most recently 2024-11-18.
CIK 0001861554
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
0 open-market purchases, against 1 sale. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| SKYE | 345,945 | $540K |
Shares reported on the most recent Form 4, priced at the 2024-11-19 close.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| SKYE | SELL | 2024-11-15 | 2024-11-19 | $4.99 | $862K | -1.2% | -33.9% | -28.2% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.